p.86 抽出テキスト

gators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279-1289. PMID: 16214598 207. Kaku K, Daida H, Kashiwagi A, et al. Long-term effects of pioglitazone in Japanese patients with type 2 diabetes without a recent history of macrovascular morbidity. Curr Med Res Opin 2009; 25: 2925- 2932. PMID: 19835463 208. Green JB, Bethel MA, Armstrong PW, et al. TECOS Study Group. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2015; 373: 232-242. PMID: 26052984 209. Scirica BM, Bhatt DL, Braunwald E, et al. SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369: 1317-1326. PMID: 23992601 210. White WB, Cannon CP, Heller SR, et al. EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013; 369: 1327-1335. PMID: 23992602 211. Rosenstock J, Perkovic V, Johansen OE, et al. CARMELINA Investigators. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. JAMA 2019; 321: 69-79. PMID: 30418475 212. ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012; 367: 319-328. PMID: 22686416 213. McGuire DK, Shih WJ, Cosentino F, et al. Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis. JAMA Cardiol 2021; 6: 148-158. PMID: 33031522 214. Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol 2021; 9: 653-662. PMID: 34425083 215. Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000; 321: 412-419. PMID: 10938049 216. Emdin CA, Rahimi K, Neal B, et al. Blood pressure lowering in type 2 diabetes: A systematic review and meta-analysis. JAMA 2015; 313: 603-615. PMID: 25668264 217. de Vries FM, Denig P, Pouwels KB, et al. Primary prevention of major cardiovascular and cerebrovascular events with statins in diabetic patients: A meta-analysis. Drugs 2012; 72: 2365-2373. PMID: 23186103 218. Saha SA, Arora RR. Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus – A pooled meta-analysis of randomized placebo-controlled clinical trials. Int J Cardiol 2010; 141: 157-166. PMID: 19232762 219. 日本循環器学会.循環器病の診断と治療に関するガイドライン

(2011年度合同研究班報告):虚血性心疾患の一次予防ガイドライン(2012年改訂版).https://www.j-circ.or.jp/cms/wp-content/ uploads/2020/02/JCS2012_shimamoto_h.pdf 220. Antithrombotic Trialists’ (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative metaanalysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-1860. PMID: 19482214 221. Ogawa H, Nakayama M, Morimoto T, et al. Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Investigators. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: A randomized controlled trial. JAMA 2008; 300: 2134-2141. PMID: 18997198 222. Zabel-Langhennig R, Ruttmann B, Schiele I, et al. 5-year controlled therapy study on the prevention of diabetic angiopathy with the platelet-function inhibitor acetylsalicylic acid. [Article in German] Z Gesamte Inn Med 1982; 37: 661-665. PMID: 7180065 223. ETDRS Investigators. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. JAMA 1992; 268: 1292-1300. PMID: 1507375 224. Belch J, MacCuish A, Campbell I, et al. Prevention of Progression of Arterial Disease and Diabetes Study Group. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008; 337: a1840. PMID: 18927173 225. De Berardis G, Sacco M, Strippoli GF, et al. Aspirin for primary pre-

vention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ 2009; 339: b4531. PMID: 19897665 226. ASCEND Study Collaborative Group. Effects of Aspirin for Primary

Prevention in Persons with Diabetes Mellitus. N Engl J Med 2018; 379: 1529-1539. PMID: 30146931 227. 坊内良太郎,近藤龍也,太田康晴,他.日本糖尿病学会コンセンサスステートメント策定に関する委員会.2型糖尿病の薬物療法のアルゴリズム.糖尿病 2022; 65: 419-434. 228. Hubert HB, Feinleib M, McNamara PM, et al. Obesity as an independent risk factor for cardiovascular disease: A 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983; 67: 968-977. PMID: 6219830 229. Chei CL, Iso H, Yamagishi K, et al. Body mass index and weight change since 20 years of age and risk of coronary heart disease among Japanese: the Japan Public Health Center-Based Study. Int J Obes (Lond) 2008; 32: 144-151. PMID: 17637701 230. Cui R, Iso H, Toyoshima H, et al. JACC Study Group. Body mass index and mortality from cardiovascular disease among Japanese men and women: The JACC study. Stroke 2005; 36: 1377-1382. PMID: 15920029 231. メタボリックシンドローム診断基準検討委員会.メタボリックシンドロームの定義と診断基準.日内会誌 2005; 94: 794-809. PMID: 15865013 232. Ninomiya T, Kubo M, Doi Y, et al. Impact of metabolic syndrome on the development of cardiovascular disease in a general Japanese population: The Hisayama study. Stroke 2007; 38: 2063-2069. PMID: 17525396 233. Kokubo Y, Okamura T, Yoshimasa Y, et al. Impact of metabolic syndrome components on the incidence of cardiovascular disease in a general urban Japanese population: The suita study. Hypertens Res 2008; 31: 2027-2035. PMID: 19098374 234. Look AHEAD Research Group. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 2013; 369: 145-154. PMID: 23796131 235. Nakao YM, Miyamoto Y, Ueshima K, et al. Effectiveness of nationwide screening and lifestyle intervention for abdominal obesity and cardiometabolic risks in Japan: The metabolic syndrome and comprehensive lifestyle intervention study on nationwide database in Japan (MetS ACTION-J study). PLoS One 2018; 13: e0190862. PMID: 29315322 236. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403. PMID: 11832527 237. Orchard TJ, Temprosa M, Goldberg R, et al. Diabetes Prevention Program Research Group. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: The Diabetes Prevention Program randomized trial. Ann Intern Med 2005; 142: 611-619. PMID: 15838067 238. 日本肥満学会.第5章メタボリックシンドローム.肥満症診療ガイドライン2016.ライフサイエンス出版 2016: 75-76. 239. Draznin B, Aroda VR, Bakris G, et al. American Diabetes Association Professional Practice Committee. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Medical Care in Diabetes 2022. Diabetes Care 2022; 45 Suppl: S113-S124. PMID: 34964843 240. Caleyachetty R, Thomas GN, Toulis KA, et al. Metabolically Healthy Obese and Incident Cardiovascular Disease Events Among 3.5 Million Men and Women. J Am Coll Cardiol 2017; 70: 1429-1437. PMID: 28911506 241. Lassale C, Tzoulaki I, Moons KGM, et al. Separate and combined associations of obesity and metabolic health with coronary heart disease: a pan-European case-cohort analysis. Eur Heart J 2018; 39: 397-406. PMID: 29020414 242. Eckel N, Li Y, Kuxhaus O, et al. Transition from metabolic healthy to unhealthy phenotypes and association with cardiovascular disease risk across BMI categories in 90 257 women (the Nurses’ Health Study): 30 year follow-up from a prospective cohort study. Lancet Diabetes Endocrinol 2018; 6: 714-724. PMID: 29859908 243. Kramer CK, Zinman B, Retnakaran R. Are metabolically healthy overweight and obesity benign conditions?: A systematic review and meta-analysis. Ann Intern Med 2013; 159: 758-769. PMID: 24297192 244. Ma C, Avenell A, Bolland M, et al. Effects of weight loss interventions for adults who are obese on mortality, cardiovascular disease, and cancer: systematic review and meta-analysis. BMJ 2017; 359: j4849. PMID: 29138133 245. Zhang X, Devlin HM, Smith B, et al. Effect of lifestyle interventions on cardiovascular risk factors among adults without impaired glucose tolerance or diabetes: A systematic review and meta-analysis. PLoS One 2017; 12: e0176436. PMID: 28493887 246. Seidelmann SB, Claggett B, Cheng S, et al. Dietary carbohydrate intake and mortality: a prospective cohort study and meta-analysis. Lancet Public Health 2018; 3: e419-e428. PMID: 30122560 247. Lu M, Wan Y, Yang B, et al. Effects of low-fat compared with high-